PSTV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Plus Therapeutics Inc (PSTV) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock lacks positive momentum, has bearish technical indicators, and its financial performance shows declining revenue and significant losses. While analysts maintain a Buy rating, the reduced price targets and dilution concerns make this a speculative play. Given the user's preference for long-term investments and the absence of strong proprietary trading signals, holding off on this stock is recommended.
The technical indicators for PSTV are bearish. The MACD histogram is negative and contracting, RSI is neutral at 37.112, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. The stock is trading near its support level of 0.233, with resistance levels at 0.268 and 0.279. Overall, there is no clear upward momentum.
The company has appointed Ron Andrews to its Board of Directors to enhance CNSide expansion efforts. Analysts see potential synergies between CNSide and Reyobiq, as well as a catalyst-rich 2026 with ongoing clinical trials.
The company's recent equity offering has caused dilution, leading to reduced price targets from analysts. Financial performance shows declining revenue (-3.19% YoY) and a significant drop in EPS (-92.00% YoY). The stock also lacks significant insider or hedge fund activity, and technical indicators are bearish.
In Q4 2025, revenue dropped by -3.19% YoY to $1,367,000. Net income improved to -$5,713,000 (up 46.37% YoY), but EPS dropped significantly by -92.00% YoY to -0.04. Gross margin remained stable at 100%. Overall, the financial performance reflects a struggling company with declining revenue and persistent losses.
Analysts maintain a Buy rating on PSTV, but price targets have been lowered due to dilution concerns. Lake Street has a $2 target, Maxim reduced its target to $1.50, and H.C. Wainwright lowered its target to $1. Analysts see potential in the company's pipeline and clinical trials but remain cautious due to financial challenges.
